Nonbismuth concomitant quadruple therapy for Helicobacter pylori eradication in Chinese regions

A meta-analysis of randomized controlled trials

Lien Chieh Lin, Tzu Herng Hsu, Kuang Wei Huang, Ka Wai Tam

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

AIM: To evaluate the applicability of nonbismuth concomitant quadruple therapy for Helicobacter pylori (H. pylori ) eradication in Chinese regions. METHODS: A systematic review and meta-analysis of randomized controlled trials was performed to evaluate the efficacy of nonbismuth concomitant quadruple therapy between sequential therapy or triple therapy for H. pylori eradication in Chinese regions. The defined Chinese regions include China, Hong Kong, Taiwan, and Singapore. The primary outcome was the H. pylori eradication rate; the secondary outcome was the compliance with therapy. The PubMed, Embase, Scopus, and Cochrane databases were searched for studies published in the period up to March 2016 with no language restriction. RESULTS: We reviewed six randomized controlled trials and 1616 patients. In 3 trials comparing concomitant quadruple therapy with triple therapy, the H. pylori eradication rate was significantly higher for 7-d nonbismuth concomitant quadruple therapy than for 7-d triple therapy (91.2% vs 77.9%, risk ratio = 1.17, 95%CI: 1.09-1.25). In 3 trials comparing quadruple therapy with sequential therapy, the eradication rate was not significant between groups (86.9% vs 86.0%). However, higher compliance was achieved with concomitant therapy than with sequential therapy. CONCLUSION: The H. pylori eradication rate was higher for nonbismuth concomitant quadruple therapy than for triple therapy. Moreover, higher compliance was achieved with nonbismuth concomitant quadruple therapy than with sequential therapy. Thus, nonbismuth concomitant quadruple therapy should be the first-line treatment in Chinese regions.

Original languageEnglish
Pages (from-to)5445-5453
Number of pages9
JournalWorld Journal of Gastroenterology
Volume22
Issue number23
DOIs
Publication statusPublished - Jun 21 2016

Fingerprint

Helicobacter pylori
Meta-Analysis
Randomized Controlled Trials
Therapeutics
Compliance
Singapore
Hong Kong
Taiwan
PubMed

Keywords

  • Chinese region
  • Helicobacter pylori eradication
  • Nonbismuth concomitant quadruple therapy
  • Peptic ulcer

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Nonbismuth concomitant quadruple therapy for Helicobacter pylori eradication in Chinese regions : A meta-analysis of randomized controlled trials. / Lin, Lien Chieh; Hsu, Tzu Herng; Huang, Kuang Wei; Tam, Ka Wai.

In: World Journal of Gastroenterology, Vol. 22, No. 23, 21.06.2016, p. 5445-5453.

Research output: Contribution to journalArticle

@article{938654a8c4b949df9dead77fc12e303b,
title = "Nonbismuth concomitant quadruple therapy for Helicobacter pylori eradication in Chinese regions: A meta-analysis of randomized controlled trials",
abstract = "AIM: To evaluate the applicability of nonbismuth concomitant quadruple therapy for Helicobacter pylori (H. pylori ) eradication in Chinese regions. METHODS: A systematic review and meta-analysis of randomized controlled trials was performed to evaluate the efficacy of nonbismuth concomitant quadruple therapy between sequential therapy or triple therapy for H. pylori eradication in Chinese regions. The defined Chinese regions include China, Hong Kong, Taiwan, and Singapore. The primary outcome was the H. pylori eradication rate; the secondary outcome was the compliance with therapy. The PubMed, Embase, Scopus, and Cochrane databases were searched for studies published in the period up to March 2016 with no language restriction. RESULTS: We reviewed six randomized controlled trials and 1616 patients. In 3 trials comparing concomitant quadruple therapy with triple therapy, the H. pylori eradication rate was significantly higher for 7-d nonbismuth concomitant quadruple therapy than for 7-d triple therapy (91.2{\%} vs 77.9{\%}, risk ratio = 1.17, 95{\%}CI: 1.09-1.25). In 3 trials comparing quadruple therapy with sequential therapy, the eradication rate was not significant between groups (86.9{\%} vs 86.0{\%}). However, higher compliance was achieved with concomitant therapy than with sequential therapy. CONCLUSION: The H. pylori eradication rate was higher for nonbismuth concomitant quadruple therapy than for triple therapy. Moreover, higher compliance was achieved with nonbismuth concomitant quadruple therapy than with sequential therapy. Thus, nonbismuth concomitant quadruple therapy should be the first-line treatment in Chinese regions.",
keywords = "Chinese region, Helicobacter pylori eradication, Nonbismuth concomitant quadruple therapy, Peptic ulcer",
author = "Lin, {Lien Chieh} and Hsu, {Tzu Herng} and Huang, {Kuang Wei} and Tam, {Ka Wai}",
year = "2016",
month = "6",
day = "21",
doi = "10.3748/wjg.v22.i23.5445",
language = "English",
volume = "22",
pages = "5445--5453",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "23",

}

TY - JOUR

T1 - Nonbismuth concomitant quadruple therapy for Helicobacter pylori eradication in Chinese regions

T2 - A meta-analysis of randomized controlled trials

AU - Lin, Lien Chieh

AU - Hsu, Tzu Herng

AU - Huang, Kuang Wei

AU - Tam, Ka Wai

PY - 2016/6/21

Y1 - 2016/6/21

N2 - AIM: To evaluate the applicability of nonbismuth concomitant quadruple therapy for Helicobacter pylori (H. pylori ) eradication in Chinese regions. METHODS: A systematic review and meta-analysis of randomized controlled trials was performed to evaluate the efficacy of nonbismuth concomitant quadruple therapy between sequential therapy or triple therapy for H. pylori eradication in Chinese regions. The defined Chinese regions include China, Hong Kong, Taiwan, and Singapore. The primary outcome was the H. pylori eradication rate; the secondary outcome was the compliance with therapy. The PubMed, Embase, Scopus, and Cochrane databases were searched for studies published in the period up to March 2016 with no language restriction. RESULTS: We reviewed six randomized controlled trials and 1616 patients. In 3 trials comparing concomitant quadruple therapy with triple therapy, the H. pylori eradication rate was significantly higher for 7-d nonbismuth concomitant quadruple therapy than for 7-d triple therapy (91.2% vs 77.9%, risk ratio = 1.17, 95%CI: 1.09-1.25). In 3 trials comparing quadruple therapy with sequential therapy, the eradication rate was not significant between groups (86.9% vs 86.0%). However, higher compliance was achieved with concomitant therapy than with sequential therapy. CONCLUSION: The H. pylori eradication rate was higher for nonbismuth concomitant quadruple therapy than for triple therapy. Moreover, higher compliance was achieved with nonbismuth concomitant quadruple therapy than with sequential therapy. Thus, nonbismuth concomitant quadruple therapy should be the first-line treatment in Chinese regions.

AB - AIM: To evaluate the applicability of nonbismuth concomitant quadruple therapy for Helicobacter pylori (H. pylori ) eradication in Chinese regions. METHODS: A systematic review and meta-analysis of randomized controlled trials was performed to evaluate the efficacy of nonbismuth concomitant quadruple therapy between sequential therapy or triple therapy for H. pylori eradication in Chinese regions. The defined Chinese regions include China, Hong Kong, Taiwan, and Singapore. The primary outcome was the H. pylori eradication rate; the secondary outcome was the compliance with therapy. The PubMed, Embase, Scopus, and Cochrane databases were searched for studies published in the period up to March 2016 with no language restriction. RESULTS: We reviewed six randomized controlled trials and 1616 patients. In 3 trials comparing concomitant quadruple therapy with triple therapy, the H. pylori eradication rate was significantly higher for 7-d nonbismuth concomitant quadruple therapy than for 7-d triple therapy (91.2% vs 77.9%, risk ratio = 1.17, 95%CI: 1.09-1.25). In 3 trials comparing quadruple therapy with sequential therapy, the eradication rate was not significant between groups (86.9% vs 86.0%). However, higher compliance was achieved with concomitant therapy than with sequential therapy. CONCLUSION: The H. pylori eradication rate was higher for nonbismuth concomitant quadruple therapy than for triple therapy. Moreover, higher compliance was achieved with nonbismuth concomitant quadruple therapy than with sequential therapy. Thus, nonbismuth concomitant quadruple therapy should be the first-line treatment in Chinese regions.

KW - Chinese region

KW - Helicobacter pylori eradication

KW - Nonbismuth concomitant quadruple therapy

KW - Peptic ulcer

UR - http://www.scopus.com/inward/record.url?scp=84979052702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979052702&partnerID=8YFLogxK

U2 - 10.3748/wjg.v22.i23.5445

DO - 10.3748/wjg.v22.i23.5445

M3 - Article

VL - 22

SP - 5445

EP - 5453

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 23

ER -